BR112022015666A2 - Vacinas intranasais de mrna - Google Patents
Vacinas intranasais de mrnaInfo
- Publication number
- BR112022015666A2 BR112022015666A2 BR112022015666A BR112022015666A BR112022015666A2 BR 112022015666 A2 BR112022015666 A2 BR 112022015666A2 BR 112022015666 A BR112022015666 A BR 112022015666A BR 112022015666 A BR112022015666 A BR 112022015666A BR 112022015666 A2 BR112022015666 A2 BR 112022015666A2
- Authority
- BR
- Brazil
- Prior art keywords
- mrna
- intranasal
- molecules
- antigens
- molecules encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157300 | 2020-02-14 | ||
| PCT/EP2021/053633 WO2021160881A1 (en) | 2020-02-14 | 2021-02-15 | Intranasal mrna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015666A2 true BR112022015666A2 (pt) | 2022-09-27 |
Family
ID=69593570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015666A BR112022015666A2 (pt) | 2020-02-14 | 2021-02-15 | Vacinas intranasais de mrna |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CA3183351A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| WO2023037320A1 (en) * | 2021-09-10 | 2023-03-16 | Intron Biotechnology, Inc. | Mucosal messenger rna vaccine |
| WO2023108076A1 (en) * | 2021-12-08 | 2023-06-15 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| WO2015071295A1 (en) * | 2013-11-12 | 2015-05-21 | Vrije Universiteit Brussel | Rna transcription vector and uses thereof |
| HRP20220070T1 (hr) * | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| DE20164728T1 (de) * | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| CN111971066B (zh) * | 2018-01-18 | 2025-03-11 | 伊泽阿恩埃免疫疗法股份有限公司 | 脂质纳米颗粒 |
-
2021
- 2021-02-15 BR BR112022015666A patent/BR112022015666A2/pt not_active IP Right Cessation
- 2021-02-15 JP JP2022548838A patent/JP2023518340A/ja active Pending
- 2021-02-15 EP EP21705192.9A patent/EP4103226A1/en not_active Withdrawn
- 2021-02-15 AU AU2021219304A patent/AU2021219304A1/en not_active Abandoned
- 2021-02-15 WO PCT/EP2021/053633 patent/WO2021160881A1/en not_active Ceased
- 2021-02-15 CA CA3170239A patent/CA3170239A1/en active Pending
- 2021-02-15 MX MX2022009943A patent/MX2022009943A/es unknown
- 2021-02-15 CN CN202180009112.1A patent/CN115443148B/zh not_active Expired - Fee Related
- 2021-02-15 KR KR1020227031704A patent/KR20230004447A/ko not_active Ceased
- 2021-02-15 US US17/799,118 patent/US20230071518A1/en not_active Abandoned
- 2021-02-15 IL IL295507A patent/IL295507A/en unknown
- 2021-02-17 TW TW110105299A patent/TW202144002A/zh unknown
-
2022
- 2022-09-01 ZA ZA2022/09779A patent/ZA202209779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170239A1 (en) | 2021-08-19 |
| ZA202209779B (en) | 2024-01-31 |
| CN115443148B (zh) | 2024-08-06 |
| WO2021160881A9 (en) | 2022-11-10 |
| MX2022009943A (es) | 2022-10-18 |
| US20230071518A1 (en) | 2023-03-09 |
| CN115443148A (zh) | 2022-12-06 |
| IL295507A (en) | 2022-10-01 |
| KR20230004447A (ko) | 2023-01-06 |
| WO2021160881A1 (en) | 2021-08-19 |
| AU2021219304A1 (en) | 2022-10-06 |
| JP2023518340A (ja) | 2023-05-01 |
| TW202144002A (zh) | 2021-12-01 |
| EP4103226A1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009943A (es) | Vacunas intranasales de arnm. | |
| Becker et al. | Influenza vaccines: successes and continuing challenges | |
| Krammer et al. | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | |
| Krammer et al. | H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge | |
| Schmolke et al. | Evasion of innate and adaptive immune responses by influenza A virus | |
| Jeon et al. | A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin | |
| Ko et al. | Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells | |
| Price et al. | Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model | |
| Kamlangdee et al. | Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene | |
| BR112017012944A2 (pt) | ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza? | |
| WO2021202734A3 (en) | Universal influenza vaccine using nucleoside-modifield mrna | |
| BRPI0817299A8 (pt) | vacinas e componentes de vacina para inibição de células microbianas | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112018075855A2 (pt) | sistema de vetor viral adeno-associado com dupla sobreposição para a expressão abc4a | |
| BR112015023886A2 (pt) | polipeptídeo, ácido nucleico, composição farmacêutica, e, método | |
| BR112015013004A2 (pt) | molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo | |
| BR112013000394A2 (pt) | composições e métodos para o tratamento de influenza | |
| Bondareva et al. | Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry | |
| Rhee et al. | Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice | |
| Teo et al. | Usp25-Erlin1/2 activity limits cholesterol flux to restrict virus infection | |
| BR112022007952A2 (pt) | Medicamento para tratar câncer, medicamento de combinação, composição de medicamento, célula imunorresponsiva, veículo de entrega de ácido nucleico e produto | |
| BR112014003278A2 (pt) | vacinas para influenza h5 | |
| Zhang et al. | Broadly protective CD8+ T cell immunity to highly conserved epitopes elicited by heat shock protein gp96-adjuvanted influenza monovalent split vaccine | |
| Jang et al. | Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2867 DE 16-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |